Anti-UGT1A1 Rabbit Antibody [B18H17]

Catalog No.: F2834

Application: Reactivity: Human

Usage Information

Dilution
WB1:1000 - 1:5000

Application
WB

Reactivity
Human

Source
Rabbit

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
60 kDa

Datasheet & SDS

Biological Description

Specificity
Anti-UGT1A1 Rabbit Antibody [B18H17] detects endogenous levels of total UGT1A1 protein.

Clone
B18H17

Synonym(s)
GNT1, UGT1, UGT1A1, UDP-glucuronosyltransferase 1A1, Bilirubin-specific UDPGT isozyme 1, UDP-glucuronosyltransferase 1-1, UDP-glucuronosyltransferase 1A isoform 1, hUG-BR1, UDPGT 1-1, UGT1*1, UGT1-01, UGT1.1

Background
UGT1A1 (UDP-glucuronosyltransferase 1A1) is a key enzyme of the UGT1 gene locus on chromosome 2q37 that detoxifies bilirubin and other lipophilic endogenous and exogenous compounds by conjugating them with glucuronic acid, enhancing solubility for excretion. Structurally, UGT1A1 shares conserved C-terminal sequences that mediate catalytic activity, while its variable N-terminal domain confers substrate specificity through alternative splicing of unique first exons. UGT1A1 is highly expressed in the liver and gastrointestinal tract, where it plays a crucial role in bilirubin clearance, drug metabolism, and protection against xenobiotic toxicity. Impaired or reduced UGT1A1 activity, due to genetic polymorphisms or regulatory defects, underlies conditions such as Gilbert’s syndrome, Crigler-Najjar syndrome, and drug-induced toxicities, highlighting its essential role in metabolism and clinical pharmacology.

Background

UGT1A1 (UDP-glucuronosyltransferase 1A1) is a key enzyme of the UGT1 gene locus on chromosome 2q37 that detoxifies bilirubin and other lipophilic endogenous and exogenous compounds by conjugating them with glucuronic acid, enhancing solubility for excretion. Structurally, UGT1A1 shares conserved C-terminal sequences that mediate catalytic activity, while its variable N-terminal domain confers substrate specificity through alternative splicing of unique first exons. UGT1A1 is highly expressed in the liver and gastrointestinal tract, where it plays a crucial role in bilirubin clearance, drug metabolism, and protection against xenobiotic toxicity. Impaired or reduced UGT1A1 activity, due to genetic polymorphisms or regulatory defects, underlies conditions such as Gilbert’s syndrome, Crigler-Najjar syndrome, and drug-induced toxicities, highlighting its essential role in metabolism and clinical pharmacology.

References
https://pubmed.ncbi.nlm.nih.gov/23089802/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%